Logo: Precision Medicine 2017



Videos with live transcript (view on DBMI website):

Videos of all sessions also available on YouTube


Bull's Eye: Precision medicine is growing up (HMS News)


Program booklet

#PM17HMS program booklet cover



Patients continue to inspire and drive us to the leading edge of precision medicine.* Along the way, these heroic acts of leadership and focus need to be translated into functional business models that can be widely adopted to transform our research and clinical care enterprise.

In this year’s conference on Wednesday, June 21 (agenda below), we address the question of how to implement and disseminate these business models head on. Fortunately there are already several enterprises, some of them led by patients themselves, which provide us early answers to these questions. These are featured in our first panel entitled Early Disruptors in Precision Medicine.

As we have noted in our prior conferences, some of the most interesting initiatives have come out of academic centers and others out of purely commercial initiatives. In our second panel entitled Academia and Industry—How Do We Play to Win?, we explore how these two wellsprings of innovation can best work together.

If we are going to succeed in the goals articulated for precision medicine, some means of measuring our success, particularly for patients and improving health, should be applied. This will allow us as a society to be more agile in finding new solutions. But without a “consumer reports” like function, progress will be difficult to measure. Our third panel, How Do We Guide the Consumer in the Precision Medicine Era?, discusses how we might think about such a consumer reports-like function and where it might sit relative to other benchmarking and regulatory processes.

Our opening keynote brings us back to the roots of this conference, which is the imperative to treat patients more successfully using the latest in clinical and molecular technology. Shirley Pepke will give us a summary of her harrowing and compelling journey to develop a successful survival plan for herself, in the face of deadly disease.

Our closing keynote by Jessica Richman, co-founder of uBiome, compliments our opening keynote by showing how citizen science can generate nationally-scaled breakaway business models.


Wednesday, June 21, 2017, 8:30 am – 5:00 pm ET


Joseph B. Martin Amphitheater, 77 Ave. Louis Pasteur, Boston


Register via Eventbrite (conference is free but space is limited)


The Inn at Longwood Medical
342 Longwood Avenue, Boston, MA 02115
617-731-4700 (Group code: PREC2017)
Click HERE to reserve at the group rate of $219/night.
Cut-off date for group rate: May 28, 2016
Courtyard Marriott Brookline
40 Webster Street (Coolidge Corner), Brookline, MA 02446
Click HERE to reserve at the group rate of $219/night.
Cut-off date for group rate: June 8, 2017


Contact us at precisionmedicine@hms.harvard.edu


Conference Agenda

Time Topic & Speaker(s)
8:30–9:00am Continental Breakfast and Check-in
9:00–9:15am Welcome — Zak Kohane, Harvard Medical School
9:15–9:30am Opening Remarks — George Daley, Dean, Harvard Medical School
9:30–10:30am Keynote — Shirley Pepke, President, Lyrid
10:30–10:45am BREAK
10:45am–12:00pm PANEL 1 — Early Disruptors in Precision Medicine
  • Jamie Heywood, Co-Founder, PatientsLikeMe
  • Noga Leviner, Co-Founder & CEO, PicnicHealth
  • Matt Might, Co-Founder, Pairnomix
  • Pamela Gavin, COO, National Organization for Rare Disorders
12:00–1:00pm LUNCH
1:00–2:15pm PANEL 2 — Academia and Industry: How Do We Play to Win?
  • Kathy Giusti, Co-Chair, HBS Kraft Precision Medicine Accelerator
  • Josh Mandel and David Kreda, Sync for Science (S4S)
  • Ethan Perlstein, CEO, Perlara
  • Joe Pickrell, Co-Founder, Seeq, Core Member, New York Genome Center
  • Giselle Sholler, Innovative Therapeutics Clinic Director, Helen DeVos Children’s Hospital; Chair, Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC)
2:15–2:30pm BREAK
2:30–3:45pm PANEL 3 — How Do We Guide the Consumer in the Precision Medicine Era?
  • Jill Hagenkord, Chief Medical Officer, Color Genomics
  • Taha Kass-Hout, MD, Founder, Kass-Hout Consulting, and former FDA 1st Chief Health Informatics Officer
  • Gary Lyman, MD, MPH, Fred Hutchinson Cancer Research Center
  • Jess Mega, Chief Medical Officer, Verily
3:45–4:00pm BREAK
4:00–5:00pm CLOSING KEYNOTE — Jessica Richman, Co-Founder & CEO, uBiome

*What do we mean by “precision medicine”? From the perspective of one of the members of the National Academy of Sciences committee that wrote the report, we mean taking an explicit multidimensional view of patients: not just one data modality such as genomics or environmental exposure. We argue that this perspective allows for more precise matching of humans to disease states (diagnosis), future disease states (prognosis) and appropriate therapies.

Conference co-sponsored by DBMI, PIC-SURE, a BD2K Center of Excellence, and Amazon Web Services